Cancer remains the primary cause of mortality around the globe, and one significant aspect for the development of efficient anticancer drugs in humans is to better understand human cancer biology during the preclinical stage of drug discovery. Researchers are developing effective preclinical models to in...
situation, generations of pre-clinical models have been developed, among which patient-derived xenografts, organoids, tumor explants, and genetically engineered mouse models emerged as complementary tools in cancer research and drug screening (Fig.1). In this review, we discuss the current status of...
The NFIB/CARM1 partnership is a driver in preclinical models of small cell lung cancer Guozhen Gao, Simone Hausmann, Natasha M. Flores, Ana Morales Benitez, Jianjun Shen, Xiaojie Yang, Maria D. Person, Sitaram Gayatri, Donghang Cheng, Yue Lu, Bin Liu, Pawel K. Mazur &...
Murine models for the study of lung cancer have historically been the backbone of preliminary preclinical data to support early human clinical trials. However, the availability of multiple experimental systems leads to debate concerning which model, if any, is best suited for a particular therapeutic...
Rexinoids are ligands which activate retinoid X receptors (RXRs), regulating transcription of genes involved in cancer-relevant processes. Rexinoids have anti-neoplastic activity in multiple preclinical studies. Bexarotene, used to treat cutaneous T cell
Organoids in cancer research The recent advances in in vitro 3D culture technologies, such as organoids, have opened new avenues for the development of novel, more physiological human cancer models. Such preclinical models are essential for more efficient translatio... J Drost,H Clevers - 《Natu...
A one-two punch of changing gene expression, then deploying immune checkpoint inhibitors, shows promise in battling one of the most treatment-resistant types of cancer in preclinical models, according to a new publication including authors from the Hacke
EJNMMI Research (2022) 12:70 https://doi.org/10.1186/s13550-022-00939-2 PRELIMINARY RESEARCH Open Access Radioimmunotherapy study of 131I‑labeled Atezolizumab in preclinical models of colorectal cancer Linhan Zhang1,2, Sheng Zhao2, Huijie Jiang2* , Rongjun Zhang3*, ...
A substantial part of all hereditary breast cancer cases is caused by BRCA1 germline mutations. In this review, we will discuss the insights into BRCA1 functions that we obtained from mouse models with conventional and conditional mutations in Brca1. The most advanced models closely resemble human...
microenvironment, are an invaluable tool to study cancer development and evaluate new therapeutic targets. Here, we discuss recent advances in LUSC preclinical models, with a focus on genetically engineered mouse models (GEMMs) and organoids, in the context of evolving precision medicine and ...